Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Research Evidence Comparison# Orforglipron# The ATTAIN program includes ATTAIN-1 (obesity, 12.4% weight loss at 36 mg, 72 weeks, published in NEJM), ATTAIN-2 (obesity + T2D, 10.5% weight loss), and ATTAIN-MAINTAIN (weight maintenance after injectable switch)
Say goodbye to waiting months to see your desired outcome
Evaluation and management of testosterone deficiency: AUA guideline
Victozas patent in the US and Europe expired in late 2023, paving the way for companies like Teva to pursue generic versions
Hannan K, Li X, Mehta A, Yenokyan G, Payne JL, Shea AA, et al
US$ 26.64
US$ 26.22
US$ 28.22
US$ 25.18
US$ 29.78
US$ 25.22
